Filing Analysis
TScan Therapeutics, Inc. announced that Amgen Inc. has exercised its right to terminate their Research Collaboration and License Agreement, effective November 10, 2026. This terminates a significant partnership aimed at identifying antigens for Crohn's disease treatment.
🚩 Red Flags
- Loss of a major strategic partner (Amgen) significantly reduces the company's potential for high-value milestone and royalty revenue.
- Loss of a primary revenue driver (the $500M+ milestone potential) which is critical for a micro-cap biotech.
- The company must now wind down research activities related to this collaboration, potentially leading to sunk costs or loss of momentum in the Crohn's disease program.
📋 Key Facts
- Amgen exercised a 90-day termination notice on August 12, 2026.
- The termination will be effective November 10, 2026.
- The original agreement (dated May 8, 2023) included a $30.0 million non-refundable upfront payment already received.
- Potential future milestone payments were valued at over $500 million in the aggregate.
- The Company will not receive future milestone or royalty payments unless Amgen or its sublicensees continue to exploit the developed product candidates.
- No early termination penalty is payable to TScan.
TScan Therapeutics, Inc. filed an 8-K to furnish its second quarter 2026 financial results via a press release. The filing is for informational purposes and does not contain material changes or specific financial data within the text provided.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Second quarter ended June 30, 2026
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the actual press release with financial results
TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA™ Phase 1 study evaluating TSC-101. The data highlights a ~90% manufacturing success rate using a commercial-ready process and significant donor chimerism achievement in patients with heme malignancies.
📋 Key Facts
- Cohort C enrollment: 19 patients.
- Manufacturing success rate: ~90% (17/19) using the commercial-ready manufacturing process.
- Transplant progress: 14 of 19 patients proceeded to transplant and received their first infusion.
- Chimerism results: 11 of 14 patients achieved complete donor chimerism within ~3 weeks; 2 others are approaching it.
- Safety profile: TSC-101 infusions were generally well-tolerated, with safety consistent with previous Cohort A data.
TScan Therapeutics stockholders approved an amendment to double the company's authorized voting common stock from 300 million to 600 million shares. The vote occurred at the 2026 Annual Meeting, where shareholders also elected Class II directors and ratified the company's independent auditor.
🚩 Red Flags
- Doubling the authorized share capital from 300 million to 600 million shares creates a massive overhang and signals potential for significant future equity dilution.
📋 Key Facts
- Stockholders approved an amendment to increase authorized voting common stock from 300,000,000 to 600,000,000 shares.
- The Certificate of Amendment was filed and became effective on May 20, 2026.
- Katina Dorton and R. Keith Woods were elected as Class II directors.
- Deloitte & Touche LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
TScan Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The company reported financial results for the quarter ended March 31, 2026.
- The report was filed on May 6, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The press release containing the detailed financial data was furnished as Exhibit 99.1.
TScan Therapeutics announced the resignation of Leiden Dworak, Vice President of Finance and Principal Accounting Officer, effective April 10, 2026. The Company's current CFO, Jason A. Amello, will assume the additional role of Principal Accounting Officer.
📋 Key Facts
- Leiden Dworak notified the company of his resignation on March 31, 2026.
- The resignation is effective April 10, 2026.
- Jason A. Amello (CFO) is appointed as the Principal Accounting Officer effective April 10, 2026.
- The company stated there were no disagreements regarding operations, policies, or practices.
- Mr. Amello will receive no additional compensation for the added responsibilities.
TScan Therapeutics announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The results were released via a press release furnished with the filing.
📋 Key Facts
- Financial results cover Q4 2025 and the full fiscal year ended December 31, 2025.
- The press release is furnished as Exhibit 99.1.
- The report was signed by CEO Gavin MacBeath, Ph.D. on March 4, 2026.
TScan Therapeutics, Inc. has released a corporate presentation in connection with the 44th Annual J.P. Morgan Healthcare Conference. The filing is intended to provide information for potential meetings with investors and analysts during the conference week.
📋 Key Facts
- Company released a Corporate Presentation (Exhibit 99.1) on January 12, 2026.
- The presentation is intended for use at the 44th Annual J.P. Morgan Healthcare Conference.
- Information was furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
TScan Therapeutics has approved a key employee retention program for its top executives, including the CEO, CFO, and CMO. The program consists of cash bonuses and restricted stock units (RSUs) tied to clinical milestones related to the TSC-101 pivotal trial.
🚩 Red Flags
- Heavy reliance on executive retention suggests potential risk in maintaining key personnel during critical clinical phases.
- Significant dilution potential from the issuance of nearly 2 million RSUs to three individuals upon milestone achievement.
📋 Key Facts
- Retention Program includes cash awards: $399,000 for CEO Gavin MacBeath, $170,000 for CFO Jason Amello, and $250,000 for CMO Chrystal Louis.
- Cash payments are split: 50% upon achievement of a milestone related to the TSC-101 pivotal trial, and 50% on the first anniversary of that milestone.
- Equity awards include RSUs: 1,000,000 for CEO, 270,000 for CFO, and 650,000 for CMO, contingent upon the TSC-101 clinical milestone.
- RSU vesting schedule: 25% on the second anniversary of the milestone; remaining 75% upon completion of the pivotal trial or the fourth anniversary of the grant date.
TScan Therapeutics, Inc. filed an 8-K to furnish its third quarter financial results for the period ending September 30, 2025. The filing serves as a formal announcement of the company's quarterly earnings via a press release.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes Exhibit 99.1 containing the quarterly press release
- Company is an emerging growth company
TScan Therapeutics is implementing a strategic realignment to prioritize its hematologic malignancies (heme) program, which includes pausing enrollment in its solid tumor Phase 1 trial and focusing on preclinical development. This restructuring involves a significant workforce reduction of approximately 30% (66 roles) and is expected to yield $45 million in annual cost savings starting in 2026.
🚩 Red Flags
- Significant workforce reduction (30%) indicating a need for aggressive cost-cutting.
- Pausing enrollment in solid tumor Phase 1 trial suggests potential setbacks or lack of confidence in the current clinical path for that asset.
- Observed instances of relapse/incomplete chimerism in TSC-101 patients due to manufacturing issues (though a new process has been implemented).
📋 Key Facts
- Workforce reduction of ~30% (66 employees).
- One-time severance charge of up to $2.3 million expected in Q4 2025.
- Strategic pivot: Prioritizing heme program; pausing solid tumor Phase 1 enrollment; focusing on preclinical in vivo engineering and autoimmunity.
- FDA agreement reached on pivotal study design for TSC-101 (heme program) using a biologically assigned internal control arm.
- TSC-101 pivotal trial expected to begin in Q2 2026.
- Cash runway extended into the second half of 2027.
- Annual cost savings of $45 million projected for 2026 and 2027.
TScan Therapeutics released an updated corporate presentation via Regulation FD disclosure. The update includes revised development timelines and pipeline updates for their solid tumor, hematologic malignancies, and autoimmunity programs.
🚩 Red Flags
- Adjusted (likely delayed) timelines for clinical/development milestones in the solid tumor program.
📋 Key Facts
- Company released an updated corporate presentation on September 9, 2025.
- The presentation contains adjusted timelines for the company's solid tumor program.
- Updates provided for pipeline development in both hematologic malignancies and solid tumors.
- Includes updates on target discovery initiatives in autoimmunity.
TScan Therapeutics, Inc. announced the appointment of Leiden Dworak as Principal Accounting Officer, effective August 14, 2025. This results in Jason A. Amello stepping down from the PAO role while maintaining his positions as CFO and PFO.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Leiden Dworak appointed as Principal Accounting Officer (PAO) effective August 14, 2025.
- Jason A. Amello ceased serving as PAO but remains Chief Financial Officer (CFO) and Principal Financial Officer (PFO).
- Mr. Dworak previously served as the Company's PAO from July 2023 to January 2024.
- Mr. Dworak brings significant biotech experience, including prior roles at AVROBIO, Inc. and Moderna, Inc.
TScan Therapeutics, Inc. filed an 8-K to furnish its second quarter financial results for the period ending June 30, 2025. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Company announced Q2 2025 financial results on August 12, 2025.
- The reporting period ended June 30, 2025.
- Financial results were released via Exhibit 99.1 as a press release.
TScan Therapeutics, Inc. reported the results of its 2025 annual meeting of stockholders held on June 30, 2025. The meeting involved the election of Class I directors and the ratification of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 30, 2025.
- Elected Stephen Biggar, M.D., Ph.D., Gavin MacBeath, Ph.D., and Garry Nicholson to Class I directors for three-year terms ending in 2028.
- Ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
- Proposal 1 (Directors) received significant votes 'For' across all candidates, though broker non-votes were notable at 14,313,890.
TScan Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the first quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard disclosure of Q1 2025 financial results (ended March 31, 2025).
- The report was filed on May 6, 2025.
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
TScan Therapeutics, Inc. filed an 8-K to furnish its financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 5, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing is a furnishing of results under Item 2.02 and does not constitute 'filed' information for liability purposes.
- Exhibit 99.1 contains the full press release regarding financial performance.
TScan Therapeutics, Inc. entered into a securities purchase agreement to issue pre-funded warrants for approximately $30 million in gross proceeds via a registered direct offering. The funds are intended for general corporate purposes and are expected to extend the company's cash runway into Q1 2027.
🚩 Red Flags
- Related-party transaction: The primary purchaser, Lynx1 Capital Management LP, is an existing shareholder.
- Pre-funded warrants: These often function as equity with a nominal exercise price to avoid certain regulatory or voting hurdles, effectively resulting in immediate dilution.
📋 Key Facts
- Registered direct offering of up to 7,500,000 pre-funded warrants.
- Warrants have a purchase price of $4.00 per warrant and an exercise price of $0.0001 per share.
- Aggregate gross proceeds are approximately $30.0 million; estimated net proceeds are $29.8 million.
- Purchasers include Lynx1 Capital Management LP (an existing shareholder) and an investment fund advised by them.
- Expected closing date is on or about December 27, 2024.
- Proceeds are expected to fund operations into the first quarter of 2027.
TScan Therapeutics entered into a new $52.5 million term loan facility with Silicon Valley Bank to refinance existing debt and provide working capital. The agreement includes milestone-based amortization terms and requires a first-priority security interest on substantially all company assets (excluding IP).
🚩 Red Flags
- Significant debt load ($52.5M) for a micro-cap biotech.
- Milestone-contingent amortization terms create liquidity pressure if clinical/financial targets are missed.
- First-priority security interest on substantially all assets (excluding IP).
- Prepayment penalties and exit fees increase the cost of capital.
📋 Key Facts
- Entered into a New Loan Agreement with Silicon Valley Bank on December 20, 2024.
- Total facility amount: $52.5 million ($32.5M Term A available immediately; $20M second tranche available at Lender's discretion by June 30, 2026).
- Term A Loan Advance used to refinance $17.2 million in existing debt and for general corporate purposes.
- Interest rate: Greater of 7.00% or Prime minus 0.75%, capped at 9.75% per annum.
- Maturity date is September 1, 2029, subject to clinical/financial milestones; otherwise moves up to September 1, 2028.
- Includes a 5.0% exit fee (final payment) and tiered prepayment penalties (3%, 2%, or 1%).
- Collateral: First-priority security interest on substantially all assets except intellectual property.
TScan Therapeutics reported positive preliminary Phase 1 data from its ALLOHA trial for TSC-100 and TSC-101, showing improved event-free survival in AML/ALL/MDS patients. The company also outlined a potential registrational pathway with the FDA and plans to launch a pivotal trial in H2 2025.
🚩 Red Flags
- Clinical trial mortality reported in one high-risk patient (relapse and subsequent mortality) following transplant without achieving complete remission.
- The company is still in the process of transferring commercial manufacturing to a CDMO, which introduces execution risk for upcoming trials.
📋 Key Facts
- ALLOHA Phase 1 trial (NCT05473910) enrolled 38 patients: 26 in treatment arm, 12 in control arm.
- Event-free survival strongly favors the treatment arm (HR=0.30; p=0.04).
- Relapse rate in treatment arm was 8% (2/26) vs. 33% (4/12) in the control arm.
- FDA feedback suggests a registrational trial using relapse-free survival (RFS) as primary endpoint and an external control arm (CIBMTR data) is acceptable.
- Company plans to launch a pivotal registrational trial for TSC-101 in the second half of 2025.
- Solid tumor program update: Eight patients infused with singleplex TCR-T; early evidence of anti-tumor activity observed.
TScan Therapeutics, Inc. announced the conversion of $15 million of principal from a convertible term loan into voting common stock. This resulted in the issuance of 3,134,796 shares to the lender at a conversion price of $4.785 per share.
🚩 Red Flags
- Debt-to-equity conversion indicates a significant reduction in liabilities but also substantial dilution for existing shareholders.
- The conversion involves a large portion ($15M) of an original $30M loan, suggesting the company is actively reducing its debt burden through equity rather than cash flow.
📋 Key Facts
- Lender exercised a conversion notice on November 15, 2024.
- Conversion amount: $15,000,000 of principal from the existing Loan and Security Agreement (dated Sept 9, 2022).
- Shares issued: 3,134,796 shares of voting common stock.
- Conversion price: $4.785 per share.
- Issuance date for shares: November 20, 2024.
- The issuance was made under the registration exemption of Section 3(a)(9) of the Securities Act.
TScan Therapeutics, Inc. filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the company's quarterly earnings via a press release.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Third quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the quarterly earnings press release
- Company is an Emerging Growth Company
TScan Therapeutics, Inc. entered into a Second Amendment to its existing lease to expand its office space in Waltham, Massachusetts. The expansion adds approximately 25,628 rentable square feet to support company operations through October 31, 2029.
🚩 Red Flags
- Increased fixed operating expenses due to significant additional monthly rent obligations.
📋 Key Facts
- Lease expansion for ~25,628 additional rentable square feet at 830 Winter Street, Waltham, MA.
- Term commences in Q4 2024 and runs through October 31, 2029.
- Additional monthly base rent starts at $163,378.50 (with escalations) after a two-month grace period.
- Landlord to provide a tenant improvement allowance of up to approximately $2,681,540.
TScan Therapeutics, Inc. filed an 8-K to furnish its second quarter 2024 financial results for the period ended June 30, 2024.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing is for the purpose of furnishing financial results via press release (Exhibit 99.1)
- The information is furnished but not filed under Section 18 of the Exchange Act
TScan Therapeutics announced leadership changes following its 2024 Annual Meeting, including the resignation of Chairman Timothy Barberich and the appointment of Stephen Biggar as Board Chair. The company also appointed Garry Nicholson to the Board and received stockholder approval for an amended equity incentive plan.
🚩 Red Flags
- Departure of the Board Chairman (though noted as non-dispute related).
📋 Key Facts
- Timothy Barberich resigned as Chairman of the Board effective June 12, 2024; resignation was not due to any disagreement with the Company.
- Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board.
- Garry Nicholson appointed to the Board as an independent director.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan, which increases reserved shares by 2,000,000 and adjusts replenishment rules for pre-funded warrants.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- Board approved stock option awards to non-employee directors totaling 308,750 shares at an exercise price of $8.88.
TScan Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the first quarter ended March 31, 2024. The filing consists of a press release and does not contain material changes to corporate structure or unexpected financial distress.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were issued via press release as Exhibit 99.1
TScan Therapeutics announced a significant equity offering involving the sale of common stock and pre-funded warrants at $7.13 per share, aimed at raising approximately $144.7 million to fund operations through Q4 2026.
🚩 Red Flags
- Significant dilution potential due to the large number of pre-funded warrants (up to 18.5M shares) which are essentially equity substitutes.
- The use of 'pre-funded warrants' is often a mechanism used when investors want to avoid immediate impact on certain metrics or when traditional share issuance is difficult, but it results in massive long-term dilution.
📋 Key Facts
- Entered into an underwriting agreement with Morgan Stanley & Co. LLC and TD Securities (USA) LLC on April 16, 2024.
- Offering includes 2,472,581 shares of common stock at $7.13 per share.
- Offering includes pre-funded warrants to purchase up to 18,577,419 shares at $7.1299 per warrant (exercise price $0.0001).
- Underwriters have a 30-day option to purchase an additional 3,157,500 shares.
- Estimated net proceeds: ~$144.7 million (base) or ~$165.9 million (if over-allotment is exercised).
- As of March 31, 2024, the company held $162.8 million in cash, cash equivalents, and marketable securities.
- The offering is expected to close on April 19, 2024.
TScan Therapeutics issued a clinical update regarding its solid tumor and heme malignancies programs. The company reported positive early data for its TSC-100/101 candidates in AML/ALL/MDS patients and provided timelines for upcoming Phase 1 dosing and data readouts.
🚩 Red Flags
- Clinical stage company: High dependency on upcoming data readouts (H2 2024) and regulatory feedback for registration trials.
📋 Key Facts
- Solid Tumor Program: Phase 1 clinical study initiated; first three patients expected to be dosed in early May 2024.
- 60% of screened patients qualify for at least one TCR-T in the ImmunoBank; 30% are eligible for multiplex therapy (T-Plex).
- Initial data from singleplex and multiplex cohorts expected in H2 2024.
- Heme Malignancies Program: All eight patients treated with TSC-100 or TSC-101 remain MRD negative and relapse-free as of April 16, 2024 (median follow-up >10 months).
- No dose-limiting toxicities observed in the heme malignancies cohort to date.
- Expansion cohorts for heme malignancies planned for Q3 2024 at the recommended Phase 2 dose level.
TScan Therapeutics, Inc. announced a leadership transition in its medical department on April 8, 2024. Dr. Chrystal U. Louis has been appointed as the new Chief Medical Officer, replacing Dr. Deborah Barton.
🚩 Red Flags
- None identified; departure is for personal reasons and includes a transition consultancy period.
📋 Key Facts
- Appointment of Chrystal U. Louis, M.D., M.P.H. as Chief Medical Officer on April 8, 2024.
- Departure of Deborah Barton, M.D. from the position of Chief Medical Officer.
- Dr. Barton will remain with the company in a consulting capacity to facilitate a smooth transition.
TScan Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing relates to the announcement of Q4 and FY 2023 financial results.
- Results were announced via a press release dated March 6, 2024.
- The information is furnished under Item 2.02 but is not considered 'filed' for purposes of Section 18 liability.
TScan Therapeutics, Inc. announced the appointment of Jason A. Amello as Chief Financial Officer, Treasurer, Principal Financial Officer, and Principal Accounting Officer, effective January 29, 2024. This appointment concludes the interim financial leadership roles previously held by CEO Gavin MacBeath and VP Finance Leiden Dworak.
📋 Key Facts
- Jason A. Amello appointed as CFO, Treasurer, principal financial officer, and principal accounting officer effective January 29, 2024.
- Amello's compensation includes a $500,000 annual base salary and a one-time payment of $60,000.
- Equity incentive includes an option to purchase 750,000 shares of common stock with a vesting schedule starting January 29, 2024.
- Amello is eligible for a discretionary bonus target of up to 40% of his base salary.
- Previous experience includes CFO roles at Candel Therapeutics and Saniona AB, and leadership positions at Akebia Therapeutics and Genzyme Corporation.